Future Directions and Clinical Implementation

Dr. Shameem asks about patients who would not be BTKi candidates, favoring BCL-2i-based regimens instead. Dr. Xavier emphasizes that everyone deserves opportunities for time-limited therapy, particularly pushing this approach even in high-risk patients. Patients with aberrant TP53 or del(17p) remain best candidates for continuous BTKi therapy, but post-BCL-2 settings rarely present patients who would not be offered BTKi options.

The availability of different binding sites with non-covalent BTKis represents slightly different mechanisms of action despite both being BTKis, providing valuable options for covalent BTKi-intolerant patients. Having pirtobrutinib available in second-line settings represents significant advancement for the field, particularly for intolerant patients, while all motivated patients with access should still consider time-limited therapy options.

Bruising remains the primary covalent BTKi toxicity concern in clinical practice, with this issue often persisting across different covalent BTKi brands. Dr. Xavier anticipates that pirtobrutinib may demonstrate improved tolerability for these patients, though clinical experience remains limited. Both physicians acknowledge that small, nagging side effects significantly impact quality of life and represent important factors alongside major toxicities like cardiotoxicity.

Dr. Xavier expresses excitement about emerging treatment landscape changes, including time-limited all-oral frontline therapy, pirtobrutinib second-line availability, and upcoming frontline data from studies 313 and 314. Dr. Shameem shares enthusiasm for frontline non-covalent BTKi data and BTK degrader development, which may further revolutionize treatment approaches.

Both physicians discuss whether chemoimmunotherapy days are ending, with rare specific scenarios remaining for IGHV-mutated patients without high-risk features, typically based on social rather than biological factors. Dr. Xavier adds excitement about upcoming second-generation BCL-2is, making him less nervous about moving pirtobrutinib earlier in treatment sequences knowing BTK degraders and next-generation BCL-2is are in development.

For community physicians with limited CLL experience, Dr. Xavier advises that pirtobrutinib clinical experience will likely be favorable for providers struggling with covalent BTKi toxicities. His clinical experience has been highly favorable, and pirtobrutinib's continuous daily dosing familiarity will likely become the predominant second-line approach as community providers gain comfort with the agent. The convenience factor aligns with patient expectations and provider comfort levels, potentially driving future second-line treatment patterns as clinical experience expands across practice settings.